[Filing Information](index=1&type=section&id=Filing%20Information) [Company and Filing Details](index=1&type=section&id=Company%20and%20Filing%20Details) This section provides the foundational details of the Form 8-K filing, including the registrant's identity, jurisdiction, trading information, and confirmation of its non-emerging growth company status - The registrant is Senseonics Holdings, Inc., incorporated in Delaware, with Commission File Number 001-37717[1](index=1&type=chunk) - The registrant is not an emerging growth company[3](index=3&type=chunk) Trading Information | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :---------------------------------------- | | Common Stock | SENS | NYSE American | [Current Report Items](index=2&type=section&id=Current%20Report%20Items) [Item 2.02 Results of Operations and Financial Condition](index=2&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) Senseonics Holdings, Inc. announced business updates and preliminary, unaudited financial information for the quarter ended September 30, 2025, via a press release issued on October 6, 2025, which is furnished as Exhibit 99.1 - On October 6, 2025, Senseonics Holdings, Inc. issued a press release announcing business updates and preliminary, unaudited financial information for the quarter ended September 30, 2025[4](index=4&type=chunk) - The press release (Exhibit 99.1) is furnished with this Form 8-K and is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934[4](index=4&type=chunk)[5](index=5&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=2&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section lists the exhibits accompanying the Form 8-K, primarily the press release containing the financial and business updates, and the interactive data for the cover page Exhibits | Exhibit Number | Description | | :------------- | :-------------------------------------------------- | | 99.1 | Press Release of Senseonics Holdings, Inc. dated October 6, 2025. | | 104 | Cover Page Interactive Data (embedded within the Inline XBRL document). | [Signatures](index=3&type=section&id=Signatures) The Form 8-K was officially signed on behalf of Senseonics Holdings, Inc. by its Chief Financial Officer, Rick Sullivan, on October 6, 2025 - The report was signed by Rick Sullivan, Chief Financial Officer of Senseonics Holdings, Inc., on October 6, 2025[10](index=10&type=chunk)

Preliminary unaudited revenue of $8.1 million for Q3 2025 Generated record quarterly new patient starts in Q3 2025 Established reverse stock split ratio of 1:20, anticipated to be effective October 17, 2025 GERMANTOWN, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced preliminary revenue ...

Group 1 - The call is focused on the Eversense 365 Commercial Update, indicating a significant update regarding the company's product and market performance [1] - Jeremy Feffer from Lifesci Advisors is leading the call, emphasizing the importance of forward-looking statements related to the company's future expectations and plans [2] - The company acknowledges the presence of risks and uncertainties that could affect actual results compared to the forward-looking statements made [3] Group 2 - Tim Goodnow, President and Chief Executive of Senseonics, is participating in the call, suggesting leadership involvement in discussing the company's strategic direction [4]

Summary of Eversense Three Sixty Five Commercial Update Call Company and Industry - **Company**: Senseonics - **Product**: Eversense three sixty five (CGM - Continuous Glucose Monitoring) - **Industry**: Diabetes care and medical devices Core Points and Arguments 1. **Commercialization Strategy Change**: Senseonics announced a memorandum of understanding with Ascensia to integrate the full CGM commercial organization back into Senseonics effective January 1, 2026, aiming for clearer focus and targeted resources to build the Eversense brand [4][5][6] 2. **Leadership Transition**: Brian Hansen, previously leading Ascensia's Eversense Commercial Operations, will become the new Chief Commercial Officer at Senseonics, bringing his leadership team to drive Eversense sales [5][6][12] 3. **Market Growth**: Eversense three sixty five has seen significant growth, with new patient starts in Q2 growing 79% year-over-year and weekly new patient shipments up nearly 50% in Q3 compared to Q2 [12][15] 4. **Record Performance**: August set records for the highest number of sensor insertions and new patient shipments in the history of Senseonics [12][13] 5. **Financial Implications**: The elimination of the Ascensia revenue share is expected to improve revenue by over 20% and gross profit margin to exceed 50% next year, with potential to reach 70% at scale [19][20] 6. **Investment in Growth**: Senseonics plans to fund additional investments in sales and marketing through improved revenue and a partnership with Hercules Capital for a non-dilutive debt facility of up to $100 million [19][20] 7. **Transition Plans**: The transition to full commercial rights is expected to be smooth, with minimal disruption for patients and providers, and is aligned with PHC's strategic focus [9][21] 8. **International Expansion**: The company is preparing for the launch of Eversense three sixty five in European markets, with activities expected to begin in Q4 upon receiving CE Mark approval [14][85] Other Important Content 1. **Patient-Centric Focus**: The integration aims to enhance patient experience and access to Eversense, with a commitment to improving the lives of people affected by diabetes [9][10] 2. **DTC Campaign Success**: The direct-to-consumer (DTC) campaign has shown promising results, with increased awareness and lead generation [53][80] 3. **Future Product Pipeline**: The transition will also support the upcoming launches of the Gemini and Freedom systems, expected in late 2026 and late 2027 respectively [22][25] 4. **Shareholder Commitment**: Ascensia, owning nearly 10% of Senseonics, intends to maintain its investment, indicating continued support for the company's growth [9][65] 5. **Operational Efficiency**: The integration of commercial and development organizations is expected to enhance operational efficiency and responsiveness to market needs [18][19] This summary encapsulates the key points discussed during the Eversense three sixty five Commercial Update Call, highlighting the strategic changes, growth metrics, financial implications, and future plans of Senseonics in the diabetes care market.

Core Viewpoint - Senseonics Holdings, Inc. is transitioning the commercialization and distribution of its Eversense 365 continuous glucose monitoring system from Ascensia Diabetes Care to itself, aiming for improved growth and operational efficiency [1][2][3]. Group 1: Transition Details - The transition will take effect on January 1, 2026, with Senseonics assuming global sales, marketing, and commercialization responsibilities [2]. - Brian Hansen, currently President of CGM at Ascensia, will join Senseonics as Chief Commercial Officer on the same date [2]. - The companies are collaborating to finalize the documentation for this transition [2]. Group 2: Strategic Rationale - The decision to bring Eversense commercialization in-house is driven by the need for strategic investment and dedicated commercial efforts to respond to market demands [3]. - Senseonics believes that unifying the Eversense business will accelerate growth and realize its full potential more effectively than under the current structure [3]. Group 3: Financial Implications - Senseonics has expanded its non-dilutive debt facility with Hercules Capital to $100 million to fund its commercial organization [1]. - The company anticipates immediate revenue improvement and gross margin expansion to 50% in 2026, with a target of over 70% gross margins at scale [4]. - For the full year 2025, Senseonics expects global net revenue to be approximately $34-38 million, with a projected doubling of its global patient base [5][6]. Group 4: Conference Call - A conference call is scheduled for September 4, 2025, at 8:00 A.M. Eastern Time to discuss the commercial transition [1][7].

Core Viewpoint - The stock price of Senseonics Holdings (SENS) has been on a bearish trend, losing 8.3% over the past week, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be increasing [1][2]. Technical Analysis - The hammer chart pattern indicates a potential bottom in the stock price, suggesting that selling pressure may be exhausting [2][5]. - A hammer pattern forms when there is a small candle body with a long lower wick, signaling that bears may be losing control over the price [4][5]. - This pattern can occur across various timeframes and is utilized by both short-term and long-term investors [5]. Fundamental Analysis - There is rising optimism among Wall Street analysts regarding the future earnings of Senseonics, which supports the potential for a trend reversal [2]. - Over the last 30 days, the consensus EPS estimate for the current year has increased by 4.5%, indicating that analysts expect better earnings than previously predicted [8]. - Senseonics currently holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10]. Indicators of Turnaround - An upward trend in earnings estimate revisions is a bullish indicator for Senseonics, as these revisions are strongly correlated with near-term stock price movements [7]. - The Zacks Rank serves as a timing indicator, suggesting that the company's prospects are beginning to improve, further supporting the potential for a turnaround [10].

分组1 - Senseonics Holdings reported a quarterly loss of $0.02 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.03 per share a year ago [1] - The company posted revenues of $6.65 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 4.46%, and up from $4.86 million year-over-year [2] - Senseonics has surpassed consensus revenue estimates three times over the last four quarters [2] 分组2 - The stock has underperformed, losing about 3.4% since the beginning of the year, while the S&P 500 gained 7.1% [3] - The company's earnings outlook and estimate revisions will be crucial for future stock performance [4][6] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $10.03 million, and -$0.07 on revenues of $36.46 million for the current fiscal year [7] 分组3 - The Medical Info Systems industry, to which Senseonics belongs, is currently in the top 30% of Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5]

Financial Data and Key Metrics Changes - In Q2 2025, net revenue grew 37% to $6.6 million compared to $4.9 million in the prior year period, driven by new Eversense three sixty five insertions [22][28] - Gross profit for Q2 2025 was $3.1 million, an increase of $2.8 million from the prior year, primarily due to increased margins on the three sixty five day product and a one-time gain of $700,000 from VAT recoveries [26][27] - Net loss decreased to $14.5 million or $0.02 loss per share in Q2 2025, compared to a net loss of $20.3 million or $0.03 loss per share in Q2 2024 [27][28] Business Line Data and Key Metrics Changes - New patient starts for Eversense increased by 79% year-over-year and 37% from Q1 2025, with leads more than doubling compared to the prior year [6][8] - The consignment channel accounted for over 40% of revenue in Q2 2025, with revenue recognized at the time of procedure [25][26] - The average selling prices in the consignment channel are approximately two times the ASPs through the Ascensia direct shipment channel [26] Market Data and Key Metrics Changes - U.S. revenue for Q2 2025 was $4.9 million, while revenue outside the U.S. was $1.7 million [22] - The company expects to double the global patient base in 2025 compared to 2024, with the majority of revenue expected in Q4 due to new patient starts and reorders [28][29] Company Strategy and Development Direction - The company aims to enhance Eversense awareness and adoption through increased direct-to-consumer (DTC) marketing and expanding the EON Care network [4][5] - Plans include launching Eversense three sixty five in Europe later this year and collaborating with other companies to improve market presence [9][10] - The company is focused on developing the Gemini and Freedom systems, targeting a U.S. submission for Gemini in mid-2026 and a launch for Freedom about a year after Gemini [15][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth of Eversense, with expectations for increased patient starts and reorders as the first three sixty five adopters approach their next insertions [7][29] - The company anticipates full-year 2025 global net revenue to be approximately $34 million to $38 million, considering various factors including regulatory approval timelines and marketing spending [28][30] - Management is monitoring the impact of tariffs and expects to mitigate negative effects while maintaining favorable gross profit margins [30] Other Important Information - The company raised approximately $78 million in gross proceeds during Q2 2025, which will support ongoing initiatives and product launches [18][20] - A reverse stock split is being considered to facilitate broader investment opportunities and inclusion in indices with stock price requirements [21][22] Q&A Session Summary Question: Retention rates for Eversense - Management indicated that historical retention rates are around 75% from sensor one to two, increasing to about 85% from sensor two to three, and about 95% from sensor three and beyond [36][37] Question: Consignment channel revenue contribution - The consignment channel is expected to continue increasing as a percentage of total revenue, supported by Medicare pricing and EON Care efforts [41][42] Question: Mix of diabetics using Eversense - Currently, approximately 75% of patients using Eversense are type 2 diabetics, reflecting a shift from the initial focus on type 1 patients [47][48] Question: EON Care revenue contribution - EON Care services contribute low single-digit percentages to revenue, but this is expected to grow as the network expands [53] Question: Commercialization of the Twist pump - The company plans significant co-marketing efforts with Sequel for the Twist pump, with a formal development agreement in place [56][57] Question: CMS proposal for competitive bidding - Management confirmed that Eversense is compensated as a medical benefit under Medicare and will not be part of the competitive bidding process [66][67] Question: Timing for EON Care benefits - The company currently has around 40 professionals in the EON Care network, with plans to increase this to 50 in the next few months and double that by 2026 [68][69]

Core Insights - Senseonics Holdings, Inc. reported a 79% increase in new patient starts in the U.S. compared to the previous year, indicating strong market demand for its Eversense 365 continuous glucose monitoring system [1][9]. Financial Performance - Total revenue for Q2 2025 was $6.6 million, a 37% increase from $4.9 million in Q2 2024. U.S. revenue was $4.9 million, up from $3.0 million, while international revenue decreased slightly to $1.7 million from $1.9 million [4][9]. - Gross profit for Q2 2025 was $3.1 million, significantly higher than $0.3 million in Q2 2024, driven by improved margins on the Eversense 365 product and a one-time recovery of previously expensed value-added tax [5]. - The net loss for Q2 2025 was $14.5 million, or $0.02 per share, an improvement from a net loss of $20.3 million, or $0.03 per share, in Q2 2024, primarily due to better gross profit margins and reduced R&D costs [8][9]. Operational Highlights - The company expanded its direct-to-consumer advertising campaign, resulting in a 50% increase in leads during the first month compared to the previous three-month average [9]. - Senseonics completed the transition of providers to its Eon Care network, now including 38 providers to enhance patient access to insertions [9]. - The company entered a commercial development agreement with Sequel Med Tech to integrate its automated insulin delivery system with Eversense 365, with a launch expected in Q4 2025 [9]. Future Outlook - For the full year 2025, Senseonics expects global net revenue to be approximately $34-38 million, anticipating a doubling of its global patient base. Revenue generation is expected to be skewed towards the second half of the year [10]. - Gross margins are projected to increase throughout 2025, with expected margins between 32.5% and 37.5% for the full year [10].

[PART I: Financial Information](index=2&type=section&id=PART%20I%3A%20Financial%20Information) This section provides the unaudited condensed consolidated financial statements and management's discussion and analysis for Senseonics Holdings, Inc [ITEM 1: Financial Statements](index=3&type=section&id=ITEM%201%3A%20Financial%20Statements) This section presents Senseonics Holdings, Inc.'s unaudited condensed consolidated financial statements and explanatory notes [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This statement provides a snapshot of the company's assets, liabilities, and equity at specific points in time Condensed Consolidated Balance Sheets (in thousands) | Metric | June 30, 2025 (Unaudited) | December 31, 2024 | | :-------------------------------- | :--------------------------------------- | :------------------------------- | | **Assets** | | | | Cash and cash equivalents | $31,518 | $74,597 | | Short term investments, net | $94,894 | — | | Total current assets | $141,588 | $91,438 | | Total assets | $150,274 | $100,438 | | **Liabilities & Equity** | | | | Total current liabilities | $14,776 | $38,849 | | Total liabilities | $55,554 | $79,337 | | Total stockholders' equity (deficit) | $94,720 | $(16,555) | - Total assets increased by approximately **$49.8 million** from December 31, 2024, to June 30, 2025, primarily due to a significant increase in short-term investments[8](index=8&type=chunk) - Total stockholders' equity shifted from a deficit of **$(16.6) million** to a positive **$94.7 million**, indicating a substantial improvement in the company's equity position[8](index=8&type=chunk) [Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) This statement details the company's revenues, expenses, and net loss over specific reporting periods Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :----------------------------------- | :-------------------------------------- | :-------------------------------------- | :------------------------------------ | :------------------------------------ | | Total revenue | $6,649 | $4,865 | $12,906 | $9,912 | | Gross profit | $3,121 | $298 | $4,626 | $633 | | Research and development expenses | $7,715 | $10,800 | $15,014 | $21,238 | | Selling, general and administrative expenses | $9,729 | $8,991 | $17,423 | $17,119 | | Operating loss | $(14,323) | $(19,493) | $(27,811) | $(37,724) | | Net Loss | $(14,501) | $(20,287) | $(28,760) | $(39,164) | | Basic net loss per common share | $(0.02) | $(0.03) | $(0.04) | $(0.06) | - Total revenue increased by **$1.78 million** (**36.7%**) for the three months ended June 30, 2025, and by **$2.99 million** (**30.2%**) for the six months ended June 30, 2025, compared to the same periods in 2024[10](index=10&type=chunk) - Gross profit significantly improved, increasing from **$0.3 million** to **$3.1 million** for the three-month period and from **$0.6 million** to **$4.6 million** for the six-month period, driven by higher revenue and lower cost of sales[10](index=10&type=chunk) - Net loss decreased for both periods, from **$(20.3) million** to **$(14.5) million** for the three months and from **$(39.2) million** to **$(28.8) million** for the six months, indicating improved financial performance[10](index=10&type=chunk) [Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit)](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders'%20Equity%20(Deficit)) This statement tracks changes in the company's equity components over specific reporting periods Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (in thousands) | Metric | June 30, 2025 | December 31, 2024 | | :--------------------------------- | :----------------------------- | :----------------------------- | | Common Stock (Amount) | $815 | $595 | | Additional Paid-In Capital | $1,070,516 | $930,724 | | Accumulated Deficit | $(976,634) | $(947,874) | | Total Stockholders' Equity (Deficit) | $94,720 | $(16,555) | - The company's total stockholders' equity significantly improved from a deficit of **$(16.6) million** at December 31, 2024, to a positive **$94.7 million** at June 30, 2025, primarily due to the issuance of common stock[12](index=12&type=chunk) - Issuance of common stock, net of issuance costs, contributed **$98.7 million** to additional paid-in capital for the six months ended June 30, 2025[12](index=12&type=chunk) - Conversion of preferred stock added **$37.6 million** to stockholders' equity during the six months ended June 30, 2025[12](index=12&type=chunk) [Unaudited Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) This statement summarizes the cash inflows and outflows from operating, investing, and financing activities Unaudited Condensed Consolidated Statements of Cash Flows (in thousands) | Cash Flow Activity | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :----------------------------------- | :-------------------------------------- | :-------------------------------------- | | Net cash used in operating activities | $(25,347) | $(31,404) | | Net cash used in investing activities | $(94,956) | $(18,150) | | Net cash provided by financing activities | $77,224 | $9,016 | | Net decrease in cash, cash equivalents, and restricted cash | $(43,079) | $(40,538) | | Cash, cash equivalents, and restricted cash at ending of period | $31,833 | $35,171 | - Net cash used in operating activities decreased by **$6.06 million**, from **$(31.4) million** in 2024 to **$(25.3) million** in 2025, reflecting improved operational efficiency[13](index=13&type=chunk) - Net cash provided by financing activities significantly increased to **$77.2 million** in 2025 from **$9.0 million** in 2024, primarily due to proceeds from public and private offerings of common stock[13](index=13&type=chunk) - The company repaid **$20.4 million** of 2025 Notes during the six months ended June 30, 2025[13](index=13&type=chunk) [Notes to Unaudited Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) This section provides detailed explanations and disclosures supporting the condensed consolidated financial statements [1. Organization and Nature of Operations](index=8&type=section&id=1.%20Organization%20and%20Nature%20of%20Operations) This note describes the company's business, its focus on CGM systems, and recent subsidiary formations - Senseonics Holdings, Inc. is a medical technology company focused on developing and manufacturing long-term, implantable continuous glucose monitoring (CGM) systems for diabetes management[14](index=14&type=chunk) - The company formed Eon Care Services, LLC and Eon Management Services, LLC in April and July 2024, respectively, as wholly-owned subsidiaries to support patient access to Eversense Systems[15](index=15&type=chunk) [2. Liquidity and Capital Resources](index=8&type=section&id=2.%20Liquidity%20and%20Capital%20Resources) This note discusses the company's financial position, historical losses, and recent capital-raising activities - The company has incurred significant net losses since inception, with a net loss of **$28.8 million** for the six months ended June 30, 2025, and an accumulated deficit of **$976.6 million**[16](index=16&type=chunk) - As of June 30, 2025, the company had unrestricted cash, cash equivalents, and marketable securities of **$126.4 million**[16](index=16&type=chunk) - Management believes the company has sufficient resources to meet anticipated operating needs for the next twelve months, alleviating prior going concern doubts, due to recent financing proceeds and existing cash[22](index=22&type=chunk) Recent Financing Activities (May 2025) | Offering Type | Gross Proceeds | Net Proceeds | | :-------------------- | :------------- | :----------- | | Public Offering | $57.5 million | $52.1 million | | Private Placement (Abbott) | $20.3 million | $20.1 million | [3. Summary of Significant Accounting Policies](index=10&type=section&id=3.%20Summary%20of%20Significant%20Accounting%20Policies) This note outlines the key accounting principles and methods used in preparing the financial statements - The unaudited consolidated financial statements are prepared in accordance with U.S. GAAP for interim financial information and SEC regulations, with certain information condensed or omitted[23](index=23&type=chunk)[24](index=24&type=chunk) - The company operates and manages its business as one segment: diabetes products and services[25](index=25&type=chunk) - Eon Care PCs are consolidated as Variable Interest Entities (VIEs) because the company is the primary beneficiary, directing significant activities and absorbing potential losses or benefits[27](index=27&type=chunk) - The company is evaluating new FASB ASUs (2023-09 and 2024-03) regarding income tax and expense disaggregation disclosures, expecting no material impact on financial statements from ASU 2023-09[29](index=29&type=chunk)[30](index=30&type=chunk) [4. Revenue Recognition](index=14&type=section&id=4.%20Revenue%20Recognition) This note describes the company's revenue streams, including sales to distributors and consignment arrangements - Revenue is generated from sales of Eversense Systems to Ascensia, third-party distributors, and strategic fulfillment partners, as well as through a consignment model with healthcare professionals[32](index=32&type=chunk) Revenue by Geographic Region (in thousands) | Region | 3 Months Ended June 30, 2025 | % of Total (2025) | 3 Months Ended June 30, 2024 | % of Total (2024) | | :------------------------ | :--------------------------- | :---------------- | :--------------------------- | :---------------- | | United States | $4,946 | 74.4% | $3,030 | 62.3% | | Outside of the United States | $1,703 | 25.6% | $1,835 | 37.7% | | **Total** | **$6,649** | **100.0%** | **$4,865** | **100.0%** | | Region | 6 Months Ended June 30, 2025 | % of Total (2025) | 6 Months Ended June 30, 2024 | % of Total (2024) | | :------------------------ | :--------------------------- | :---------------- | :--------------------------- | :---------------- | | United States | $9,441 | 73.2% | $6,706 | 67.7% | | Outside of the United States | $3,465 | 26.8% | $3,206 | 32.3% | | **Total** | **$12,906** | **100.0%** | **$9,912** | **100.0%** | Revenue Concentration (Sales to Ascensia) | Period | % of Total Revenue | | :-------------------------- | :----------------- | | 3 Months Ended June 30, 2025 | 52% | | 3 Months Ended June 30, 2024 | 84% | | 6 Months Ended June 30, 2025 | 61% | | 6 Months Ended June 30, 2024 | 86% | Consignment Sales as % of Total Revenue | Period | % of Total Revenue | | :-------------------------- | :----------------- | | 3 Months Ended June 30, 2025 | 40.9% | | 3 Months Ended June 30, 2024 | 14.7% | | 6 Months Ended June 30, 2025 | 32.5% | | 6 Months Ended June 30, 2024 | 11.3% | [5. Net Loss per Share](index=16&type=section&id=5.%20Net%20Loss%20per%20Share) This note details the calculation of basic and diluted net loss per common share for the periods presented Net Loss Per Share (in thousands) | Metric | 3 Months Ended June 30, 2025 | 3 Months Ended June 30, 2024 | 6 Months Ended June 30, 2025 | 6 Months Ended June 30, 2024 | | :--------------------------------- | :--------------------------- | :--------------------------- | :--------------------------- | :--------------------------- | | Net loss | $(14,501) | $(20,287) | $(28,760) | $(39,164) | | Basic and diluted net loss per share | $(0.02) | $(0.03) | $(0.04) | $(0.06) | - Basic and diluted net loss per common share improved from **$(0.03)** to **$(0.02)** for the three months ended June 30, 2025, and from **$(0.06)** to **$(0.04)** for the six months ended June 30, 2025[40](index=40&type=chunk) - Potentially dilutive common shares are excluded from diluted net loss per share calculations during periods of net loss as their effect would be anti-dilutive[39](index=39&type=chunk) [6. Composition of Certain Financial Statement Items](index=18&type=section&id=6.%20Composition%20of%20Certain%20Financial%20Statement%20Items) This note provides a breakdown of key balance sheet accounts, including cash, receivables, and inventory Cash, Cash Equivalents, and Restricted Cash (in thousands) | Item | June 30, 2025 | December 31, 2024 | | :------------------------------------ | :------------ | :---------------- | | Cash | $2,183 | $3,984 | | Money market funds | $29,335 | $70,613 | | Restricted Cash | $315 | $315 | | **Total** | **$31,833** | **$74,912** | Accounts Receivable, net (in thousands) | Item | June 30, 2025 | December 31, 2024 | | :-------------------------------- | :------------ | :---------------- | | Accounts receivable | $3,661 | $1,695 | | Accounts receivable - related parties | $2,304 | $4,921 | | Less: allowance for credit losses | $(808) | $(330) | | **Total accounts receivable, net** | **$5,157** | **$6,286** | Inventory, net (in thousands) | Item | June 30, 2025 | December 31, 2024 | | :---------------- | :------------ | :---------------- | | Finished goods | $1,520 | $781 | | Work-in-process | $2,574 | $3,213 | | Raw materials | $620 | $427 | | **Total** | **$4,714** | **$4,421** | - The company capitalized costs related to 365-day product inventory starting September 2024 after FDA 510(k) clearance, which resulted in lower cost of sales as pre-clearance inventory was sold[44](index=44&type=chunk) [7. Marketable Securities](index=20&type=section&id=7.%20Marketable%20Securities) This note details the company's investments in marketable securities, including their fair value and maturity profiles Marketable Securities Available for Sale (June 30, 2025, in thousands) | Type | Amortized Cost | Estimated Market Value | | :-------------------------- | :------------- | :--------------------- | | Commercial Paper | $14,384 | $14,382 | | Corporate debt securities | $9,178 | $9,184 | | Government and agency securities | $71,309 | $71,328 | | **Total** | **$94,871** | **$94,894** | - There were no marketable securities held as of December 31, 2024, indicating a significant investment in these assets during the first half of 2025[46](index=46&type=chunk) - The majority of marketable securities mature in 2025 (remaining six months) and 2026[47](index=47&type=chunk) [8. Prepaid Expenses and Other Current Assets](index=20&type=section&id=8.%20Prepaid%20Expenses%20and%20Other%20Current%20Assets) This note provides a breakdown of the company's prepaid expenses and other current assets Prepaid Expenses and Other Current Assets (in thousands) | Item | June 30, 2025 | December 31, 2024 | | :-------------------------------- | :------------ | :---------------- | | Tax credits receivable | $1,793 | $1,793 | | Contract manufacturing | $1,635 | $2,720 | | Clinical and Preclinical | $639 | $689 | | **Total** | **$4,990** | **$5,819** | [9. Accrued Expenses and Other Current Liabilities](index=22&type=section&id=9.%20Accrued%20Expenses%20and%20Other%20Current%20Liabilities) This note details the composition of the company's accrued expenses and other current liabilities Accrued Expenses and Other Current Liabilities (in thousands) | Item | June 30, 2025 | December 31, 2024 | | :-------------------------------- | :------------ | :---------------- | | Compensation and benefits | $2,810 | $5,311 | | Professional and administrative services | $2,646 | $1,587 | | Research and development | $2,494 | $3,416 | | Sales and marketing services | $2,093 | $1,287 | | Contract manufacturing | $1,044 | $1,813 | | **Total** | **$12,507** | **$15,506** | [10. Leases](index=22&type=section&id=10.%20Leases) This note outlines the company's operating lease arrangements for its corporate headquarters - The company leases approximately 33,000 square feet of research and office space for its corporate headquarters under a non-cancelable operating lease expiring May 31, 2033[51](index=51&type=chunk) Operating Lease Assets and Liabilities (in thousands) | Item | June 30, 2025 | December 31, 2024 | | :-------------------------- | :------------ | :---------------- | | Operating lease ROU assets | $4,653 | $4,837 | | Current operating lease liabilities | $462 | $429 | | Non-current operating lease liabilities | $5,548 | $5,785 | | **Total operating lease liabilities** | **$6,010** | **$6,214** | - The weighted-average remaining lease term for operating leases is **7.9 years**, with a weighted-average discount rate of **8.5%** as of June 30, 2025[53](index=53&type=chunk) [11. Product Warranty Obligations](index=24&type=section&id=11.%20Product%20Warranty%20Obligations) This note describes the company's product warranty policy and the associated liability - The company provides a one-year warranty on its smart transmitters and may replace Eversense System components not functioning to specifications[54](index=54&type=chunk) Estimated Warranty Liabilities (in thousands) | Item | June 30, 2025 | December 31, 2024 | | :-------------------------------- | :------------ | :---------------- | | Balance at beginning of the period | $406 | $514 | | Provision for warranties during the period | $185 | $311 | | Settlements made during the period | $(161) | $(419) | | **Balance at end of the period** | **$430** | **$406** | [12. Notes Payable, Preferred Stock and Stock Purchase Warrants](index=24&type=section&id=12.%20Notes%20Payable%2C%20Preferred%20Stock%20and%20Stock%20Purchase%20Warrants) This note details the company's debt instruments, including term loans and the repayment of 2025 Notes - The company entered into a Loan and Security Agreement in September 2023 for up to **$50.0 million** in senior secured term loans, with **$35.0 million** funded as of June 30, 2025[56](index=56&type=chunk)[79](index=79&type=chunk) - The 2025 Notes, with an aggregate principal amount of **$20.4 million** outstanding at December 31, 2024, were fully repaid on January 15, 2025[70](index=70&type=chunk)[79](index=79&type=chunk) Notes Payable Carrying Amounts (in thousands) | Item | June 30, 2025 | December 31, 2024 | | :-------------------------- | :------------ | :---------------- | | Loan and Security Agreement | $35,230 | $34,703 | | 2025 Notes | — | $20,138 | | **Total** | **$35,230** | **$54,841** | Interest Expense on Notes Payable (in thousands) | Item | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :-------------------------- | :--------------------------- | :--------------------------- | | 2025 Notes | $305 | $1,920 | | Loan and Security Agreement | $2,269 | $2,213 | | **Total** | **$2,574** | **$4,133** | [13. Stockholders' Equity](index=32&type=section&id=13.%20Stockholders'%20Equity) This note details changes in the company's equity, including recent public and private offerings Equity Offerings (May 2025) | Offering Type | Gross Proceeds | Net Proceeds | | :-------------------- | :------------- | :----------- | | Public Offering | $57.5 million | $52.1 million | | Private Placement (Abbott) | $20.3 million | $20.1 million | - The Equity Distribution Agreement with Goldman Sachs & Co. LLC was terminated on May 15, 2025, having generated approximately **$30.8 million** in net proceeds from the sale of **40,130,560 shares**[84](index=84&type=chunk) [14. Stock-Based Compensation](index=33&type=section&id=14.%20Stock-Based%20Compensation) This note describes the company's equity incentive plans and employee stock purchase plan - The 2015 Equity Incentive Plan, Inducement Plan, and 2023 Commercial Equity Plan are active for granting stock options and restricted stock units to employees and non-employees[85](index=85&type=chunk)[87](index=87&type=chunk)[88](index=88&type=chunk) - As of June 30, 2025, **28,704,491 shares** remained available for grant under the Amended and Restated 2015 Plan[86](index=86&type=chunk) - The 2016 Employee Stock Purchase Plan (ESPP) allows participants to purchase common stock at **85%** of the lower of the fair market value on the offering or purchase date, with **28,299,743 shares** available for issuance[89](index=89&type=chunk)[90](index=90&type=chunk) [15. Fair Value Measurements](index=35&type=section&id=15.%20Fair%20Value%20Measurements) This note provides information on the fair value hierarchy of the company's financial assets Fair Value Hierarchy of Financial Assets (June 30, 2025, in thousands) | Asset Class | Total | Level 1 | Level 2 | Level 3 | | :-------------------------------- | :---- | :------ | :------ | :------ | | Money market funds | $29,335 | $29,335 | — | — | | Commercial paper (>3 months) | $14,382 | — | $14,382 | — | | Corporate debt securities | $9,183 | — | $9,183 | — | | Government and agency securities (>3 months) | $71,328 | $71,328 | — | — | - As of December 31, 2024, money market funds were the only financial asset measured at fair value on a recurring basis, totaling **$70.6 million**[94](index=94&type=chunk) [16. Income Taxes](index=37&type=section&id=16.%20Income%20Taxes) This note discusses the company's income tax position and the impact of recent tax legislation - The company has not recorded any tax provision or benefit for the three and six months ended June 30, 2025 or 2024, due to a full valuation allowance against net deferred tax assets[95](index=95&type=chunk) - The recently signed One Big Beautiful Bill Act (OBBBA) is being evaluated but is not expected to have a material impact on the company's consolidated financial statements[96](index=96&type=chunk) [17. Related Party Transactions](index=37&type=section&id=17.%20Related%20Party%20Transactions) This note discloses significant transactions with related parties, primarily Ascensia - Ascensia, a related party through its parent company PHC, is a significant customer, accounting for **52%** and **61%** of total revenue for the three and six months ended June 30, 2025, respectively[97](index=97&type=chunk)[98](index=98&type=chunk) Related Party Transactions with Ascensia (in thousands) | Item | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :-------------------------------- | :--------------------------- | :--------------------------- | | Revenue from Ascensia | $7,900 | $8,500 | | Commissions earned by Ascensia | $2,600 | $200 | | Amount due from Ascensia | $2,300 | $4,900 | | Amount due to Ascensia | $2,600 | $1,800 | [18. Segment Information](index=38&type=section&id=18.%20Segment%20Information) This note confirms the company operates as a single reportable segment and provides key expense categories - The company operates as a single reportable segment, deriving revenue from diabetes products and services[101](index=101&type=chunk) Key Expense Categories (in thousands) | Expense Category | 3 Months Ended June 30, 2025 | 3 Months Ended June 30, 2024 | 6 Months Ended June 30, 2025 | 6 Months Ended June 30, 2024 | | :-------------------------------- | :--------------------------- | :--------------------------- | :--------------------------- | :--------------------------- | | Cost of sales | $3,528 | $4,567 | $8,280 | $9,279 | | Sales and marketing expenses | $2,800 | $1,754 | $4,542 | $3,281 | | Research and development expenses | $7,715 | $10,800 | $15,014 | $21,238 | | General and administrative expenses | $6,929 | $7,237 | $12,881 | $13,838 | [19. Subsequent Events](index=38&type=section&id=19.%20Subsequent%20Events) This note confirms the evaluation of events occurring after the reporting period, with no material disclosures required - The company evaluated all subsequent events through the filing date of this Form 10-Q and found no events requiring recognition or disclosure[104](index=104&type=chunk) [ITEM 2: Management's Discussion and Analysis of Financial Condition and Results of Operations](index=39&type=section&id=ITEM%202%3A%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial condition, operational results, Eversense CGM commercialization, and future product development [Overview](index=39&type=section&id=Overview) This section introduces Senseonics' core business, key product developments, and strategic initiatives - Senseonics is a medical technology company focused on long-term implantable continuous glucose monitoring (CGM) systems, including Eversense E3 (180-day) and Eversense 365 (365-day)[108](index=108&type=chunk) - Eversense 365 received FDA approval in September 2024 and began commercialization in the US in Q4 2024, offering a 365-day extended life CGM system[108](index=108&type=chunk)[123](index=123&type=chunk) - Medicare coverage for Eversense E3 expanded in February 2024 to include all insulin users and non-insulin users with problematic hypoglycemia, significantly increasing patient access[112](index=112&type=chunk) - The company fully transitioned its network of inserters to Eon Care in Q2 2025, expecting this to enable a self-sustaining economic model for insertion services[126](index=126&type=chunk) - First-in-human testing for the next-generation Gemini product, a fully implantable self-powering system with both flash glucose monitoring and traditional CGM capabilities, began in July 2024[128](index=128&type=chunk) - The company plans to submit Eversense 365 for CE Mark approval in Q1 2025, with a potential launch in European markets in H2 2025[130](index=130&type=chunk)[131](index=131&type=chunk) [Financial Overview](index=45&type=section&id=Financial%20Overview) This section summarizes the company's revenue sources, including sales to distributors and consignment models - Revenue is primarily generated from sales of Eversense systems to Ascensia and other distributors, and through a consignment model with healthcare professionals[132](index=132&type=chunk) - Sales to Ascensia accounted for **52%** and **61%** of total revenue for the three and six months ended June 30, 2025, respectively, a decrease from **84%** and **86%** in the prior year, indicating diversification[137](index=137&type=chunk) - Consignment sales significantly increased, accounting for **40.9%** and **32.5%** of total revenue for the three and six months ended June 30, 2025, up from **14.7%** and **11.3%** in the prior year[138](index=138&type=chunk) Revenue by Geographic Region (in thousands) | Region | 3 Months Ended June 30, 2025 | % of Total (2025) | 3 Months Ended June 30, 2024 | % of Total (2024) | | :------------------------ | :--------------------------- | :---------------- | :--------------------------- | :---------------- | | United States | $4,946 | 74.4% | $3,030 | 62.3% | | Outside of the United States | $1,703 | 25.6% | $1,835 | 37.7% | | **Total** | **$6,649** | **100.0%** | **$4,865** | **100.0%** | | Region | 6 Months Ended June 30, 2025 | % of Total (2025) | 6 Months Ended June 30, 2024 | % of Total (2024) | | :------------------------ | :--------------------------- | :---------------- | :--------------------------- | :---------------- | | United States | $9,441 | 73.2% | $6,706 | 67.7% | | Outside of the United States | $3,465 | 26.8% | $3,206 | 32.3% | | **Total** | **$12,906** | **100.0%** | **$9,912** | **100.0%** | [Results of Operations for the Three Months Ended June 30, 2025 and 2024](index=48&type=section&id=Results%20of%20Operations%20for%20the%20Three%20Months%20Ended%20June%2030%2C%202025%20and%202024) This section analyzes the company's financial performance for the three-month periods, highlighting revenue, gross profit, and expense trends Financial Performance (Three Months Ended June 30, in thousands) | Metric | 2025 | 2024 | Period-to-Period Change | | :----------------------------------- | :----- | :----- | :---------------------- | | Total revenue | $6,649 | $4,865 | $1,784 | | Cost of sales | $3,528 | $4,567 | $(1,039) | | Gross profit | $3,121 | $298 | $2,823 | | Research and development expenses | $7,715 | $10,800 | $(3,085) | | Selling, general and administrative expenses | $9,729 | $8,991 | $738 | | Operating loss | $(14,323) | $(19,493) | $5,170 | | Net Loss | $(14,501) | $(20,287) | $5,786 | - Total revenue increased by **$1.78 million**, primarily driven by US sales growth from the consignment program and 365-day product demand[142](index=142&type=chunk) - Gross margin improved significantly to **46.9%** in 2025 from **6.1%** in 2024, due to favorable margins on 365-day product sales, lower fixed manufacturing costs, and a **$0.7 million** VAT recovery[143](index=143&type=chunk) - Research and development expenses decreased by **$3.1 million**, mainly due to the completion of Eversense 365 system clinical trials and development efforts[144](index=144&type=chunk) - Selling, general and administrative expenses increased by **$0.7 million**, driven by higher sales commission expenses to Ascensia and increased personnel costs for Eon Care subsidiaries, partially offset by lower legal expenses[145](index=145&type=chunk) [Results of Operations for the Six Months Ended June 30, 2025 and 2024](index=51&type=section&id=Results%20of%20Operations%20for%20the%20Six%20Months%20Ended%20June%2030%2C%202025%20and%202024) This section analyzes the company's financial performance for the six-month periods, detailing revenue, gross profit, and expense changes Financial Performance (Six Months Ended June 30, in thousands) | Metric | 2025 | 2024 | Period-to-Period Change | | :----------------------------------- | :----- | :----- | :---------------------- | | Total revenue | $12,906 | $9,912 | $2,994 | | Cost of sales | $8,280 | $9,279 | $(999) | | Gross profit | $4,626 | $633 | $3,993 | | Research and development expenses | $15,014 | $21,238 | $(6,224) | | Selling, general and administrative expenses | $17,423 | $17,119 | $304 | | Operating loss | $(27,811) | $(37,724) | $9,913 | | Net Loss | $(28,760) | $(39,164) | $10,404 | - Total revenue increased by **$3.0 million**, primarily due to sales growth in the US driven by the consignment program and demand for the 365-day product[148](index=148&type=chunk) - Gross margin improved to **35.8%** in 2025 from **6.4%** in 2024, benefiting from favorable margins on 365-day product sales, lower fixed manufacturing costs, VAT recoveries, and the sale of previously expensed inventory[149](index=149&type=chunk) - Research and development expenses decreased by **$6.2 million**, mainly due to the completion of Eversense 365 system clinical trials[150](index=150&type=chunk) - Selling, general and administrative expenses increased by **$0.3 million**, driven by higher sales commission expenses to Ascensia and personnel costs for Eon Care subsidiaries, offset by a decrease in legal expenses[152](index=152&type=chunk) [Liquidity and Capital Resources](index=53&type=section&id=Liquidity%20and%20Capital%20Resources) This section discusses the company's financial position, historical funding, and current capital availability - The company has an accumulated deficit of **$976.6 million** as of June 30, 2025, and has historically funded operations through equity, warrants, convertible notes, and debt[154](index=154&type=chunk) - As of June 30, 2025, unrestricted cash, cash equivalents, and marketable securities totaled **$126.4 million**[154](index=154&type=chunk) Recent Equity Financing (May 2025) | Offering Type | Net Proceeds | | :-------------------- | :----------- | | Public Offering | $52.1 million | | Private Placement (Abbott) | $20.1 million | - Management believes the company has sufficient resources for the next twelve months, alleviating prior going concern doubts, due to recent financing and existing cash[161](index=161&type=chunk)[163](index=163&type=chunk) [Cash Flows](index=56&type=section&id=Cash%20Flows) This section analyzes the company's cash flows from operating, investing, and financing activities Summary of Cash Flows (Six Months Ended June 30, in thousands) | Cash Flow Activity | 2025 | 2024 | | :------------------------------------ | :--------- | :--------- | | Net cash used in operating activities | $(25,347) | $(31,404) | | Net cash used in investing activities | $(94,956) | $(18,150) | | Net cash provided by financing activities | $77,224 | $9,016 | | Net decrease in cash, cash equivalents and restricted cash | $(43,079) | $(40,538) | - Net cash used in operating activities decreased by **$6.06 million**, driven by a lower net loss and changes in operating assets and liabilities[166](index=166&type=chunk)[167](index=167&type=chunk) - Net cash used in investing activities increased significantly to **$95.0 million** in 2025, primarily due to **$94.4 million** in marketable securities purchases[168](index=168&type=chunk) - Net cash provided by financing activities increased to **$77.2 million**, mainly from **$72.3 million** in net proceeds from public and private stock offerings, offset by **$20.4 million** repayment of 2025 Notes[170](index=170&type=chunk) [ITEM 3: Quantitative and Qualitative Disclosures About Market Risk](index=58&type=section&id=ITEM%203%3A%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, Senseonics is exempt from providing quantitative and qualitative market risk disclosures - The company is exempt from providing quantitative and qualitative disclosures about market risk due to its status as a 'smaller reporting company' under SEC rules[173](index=173&type=chunk) [ITEM 4: Controls and Procedures](index=58&type=section&id=ITEM%204%3A%20Controls%20and%20Procedures) Management assessed disclosure controls and procedures as effective, with no material changes in internal control over financial reporting - Disclosure controls and procedures were evaluated as effective at the reasonable assurance level as of June 30, 2025[174](index=174&type=chunk) - No material changes in internal control over financial reporting occurred during the quarter ended June 30, 2025[175](index=175&type=chunk) [PART II: Other Information](index=58&type=section&id=PART%20II%3A%20Other%20Information) This section provides additional information, including legal proceedings, risk factors, and other required disclosures [ITEM 1: Legal Proceedings](index=58&type=section&id=ITEM%201%3A%20Legal%20Proceedings) The company faces a patent infringement lawsuit, currently stayed pending USPTO Inter Partes Review proceedings and a Director's review - The company is a defendant in a patent infringement lawsuit filed by Cellspin Soft, Inc. in May 2024, alleging infringement of three patents[178](index=178&type=chunk) - The lawsuit is currently stayed pending resolution of Inter Partes Review (IPR) proceedings at the USPTO, which are challenging the validity of the asserted patents[178](index=178&type=chunk) - The IPR proceedings are further stayed pending a sua sponte review by the Acting Director of the USPTO regarding TikTok Inc.'s Chinese ownership status[178](index=178&type=chunk) [ITEM 1A: Risk Factors](index=60&type=section&id=ITEM%201A%3A%20Risk%20Factors) Updated risk factors highlight dependence on Ascensia, early commercialization challenges, trade policy impacts, and talent retention - The company's success is highly dependent on Ascensia's effective marketing and sales of Eversense under the Commercialization Agreement, which may not be successful[182](index=182&type=chunk)[185](index=185&type=chunk) - Challenges to Eversense adoption are being addressed through initiatives like establishing Eon Care for insertion services and increasing direct-to-consumer (DTC) spending[183](index=183&type=chunk) - The company faces difficulties inherent in early commercialization, including expanding sales infrastructure, increasing brand awareness, managing operations, and responding to competitive pressures[186](index=186&type=chunk)[187](index=187&type=chunk)[189](index=189&type=chunk) - International trade policies, including tariffs and trade barriers, pose risks to the global supply chain, production costs, and profitability, with limited ability to pass increased costs to customers due to medical device pricing structures[201](index=201&type=chunk)[203](index=203&type=chunk)[205](index=205&type=chunk) - Future success depends on generating significant sales to achieve profitability and retaining key executives and qualified personnel in a competitive talent market[211](index=211&type=chunk)[212](index=212&type=chunk)[213](index=213&type=chunk) [ITEM 2: Unregistered Sales of Equity Securities and Use of Proceeds](index=72&type=section&id=ITEM%202%3A%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This item is not applicable to the company for this reporting period - This section is marked as 'Not applicable' for the current reporting period[219](index=219&type=chunk) [ITEM 3: Defaults Upon Senior Securities](index=72&type=section&id=ITEM%203%3A%20Defaults%20Upon%20Senior%20Securities) This item is not applicable to the company for this reporting period - This section is marked as 'Not applicable' for the current reporting period[220](index=220&type=chunk) [ITEM 4: Mine Safety Disclosures](index=72&type=section&id=ITEM%204%3A%20Mine%20Safety%20Disclosures) This item is not applicable to the company for this reporting period - This section is marked as 'Not applicable' for the current reporting period[221](index=221&type=chunk) [ITEM 5: Other Information](index=72&type=section&id=ITEM%205%3A%20Other%20Information) During the fiscal quarter ended June 30, 2025, a director adopted a Rule 10b5-1 trading plan for the sale of 83,900 shares of common stock, with no sales to be made prior to September 5, 2025 Director Trading Arrangement (Adopted May 29, 2025) | Name and Position | Action | Adoption Date | Rule 10b5-1 | Total Shares to be Sold | Expiration Date | | :---------------- | :----- | :------------ | :---------- | :---------------------- | :-------------- | | Douglas S. Prince, Director | Adopted | 5/29/2025 | X | 83,900 | November 20, 2025 | - No sales will be made under the adopted trading plan prior to September 5, 2025[223](index=223&type=chunk) [ITEM 6: Exhibits](index=73&type=section&id=ITEM%206%3A%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including corporate governance documents and certifications - Exhibits include Amended and Restated Certificate of Incorporation, Bylaws, Securities Purchase Agreement with Abbott Laboratories, and certifications under Sections 302 and 906 of the Sarbanes-Oxley Act[228](index=228&type=chunk) [SIGNATURES](index=74&type=section&id=SIGNATURES) The report is duly signed on behalf of Senseonics Holdings, Inc. by Rick Sullivan, Chief Financial Officer, on August 6, 2025 - The report was signed by Rick Sullivan, Chief Financial Officer, on August 6, 2025[232](index=232&type=chunk)